摘要
目的通过meta分析对重组人类促红细胞生成素(rhEPO)治疗早产儿贫血的疗效以及剂量与疗效的关系进行评价。方法检索"PubMed"、"CNKI"等数据库,按纳入标准筛选文献后提取相关数据,使用Stata11软件进行数据分析。结果应用rhEPO后,治疗组血红蛋白、红细胞压积、网织红细胞和红细胞计数均显著高于对照组(P<0.01),表明rhEPO能有效促进红细胞生成,减轻早产儿出生后Hb和Hct的下降,提高RBC和Ret水平。结论 rhEPO治疗早产儿贫血,具有较好的疗效,值得在临床推广应用。
Objective： To evaluate the efficacy of recombinant human erythropoietin on anemia in premature infants.Methods： According to the inclusion criteria,the studies related to rhEPO in the treatment of anemia were searched from Pubmed and CNKI online databases.Related variables were extracted and analyzed with the software Stata 11.Results： Our results indicated that the difference of Hb,Hct,Ret and RBC between two groups had statistical significance（P0.01）.Conclusions： The therapy of rhEPO showed better healing efficacy than conventional therapy.
出处
《中国优生与遗传杂志》
2013年第5期100-103,共4页
Chinese Journal of Birth Health & Heredity
